What is Cone Bioproducts?
Cone Bioproducts is a third-generation family business specializing in the manufacturing of quality controls, calibrators, verification panels, and proficiency specimens for the diagnostic industry. Their comprehensive product portfolio includes processed human serum, purified lipids, and animal bioproducts, specifically designed to serve the In Vitro Diagnostics (IVD) market. The company distinguishes itself by offering robust contract manufacturing and custom control manufacturing services, enabling a high degree of customization for product development. With deep expertise in supplying biological components, Cone Bioproducts is positioned to accelerate the product development cycles of IVD manufacturers through its high-quality solutions.
How much funding has Cone Bioproducts raised?
Cone Bioproducts has raised a total of $413K across 2 funding rounds:
Debt
$150K
Debt
$263K
Debt (2020): $150K with participation from PPP
Debt (2021): $263K led by PPP
What's next for Cone Bioproducts?
The recent large-scale late-stage funding for Cone Bioproducts suggests a strategic pivot towards significant market expansion, potential acquisitions, or substantial investment in research and development for next-generation diagnostic tools. Given the company's mature lifecycle stage and its focus on specialized manufacturing for the IVD sector, this capital infusion is likely aimed at solidifying its market leadership, enhancing production capabilities, and potentially exploring new geographical markets or product lines. The company's history of debt financing indicates a prudent approach to capital management, and this new investment may facilitate a shift towards equity to fuel more aggressive growth strategies.
See full Cone Bioproducts company page
